1. Home
  2. PCRX vs LOB Comparison

PCRX vs LOB Comparison

Compare PCRX & LOB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PCRX
  • LOB
  • Stock Information
  • Founded
  • PCRX 2006
  • LOB 2008
  • Country
  • PCRX United States
  • LOB United States
  • Employees
  • PCRX N/A
  • LOB N/A
  • Industry
  • PCRX Biotechnology: Pharmaceutical Preparations
  • LOB Major Banks
  • Sector
  • PCRX Health Care
  • LOB Finance
  • Exchange
  • PCRX Nasdaq
  • LOB Nasdaq
  • Market Cap
  • PCRX 1.2B
  • LOB 1.4B
  • IPO Year
  • PCRX 2011
  • LOB 2015
  • Fundamental
  • Price
  • PCRX $23.96
  • LOB $32.27
  • Analyst Decision
  • PCRX Strong Buy
  • LOB Hold
  • Analyst Count
  • PCRX 6
  • LOB 3
  • Target Price
  • PCRX $33.83
  • LOB $40.00
  • AVG Volume (30 Days)
  • PCRX 769.6K
  • LOB 250.3K
  • Earning Date
  • PCRX 11-06-2025
  • LOB 10-22-2025
  • Dividend Yield
  • PCRX N/A
  • LOB 0.37%
  • EPS Growth
  • PCRX N/A
  • LOB N/A
  • EPS
  • PCRX 0.47
  • LOB 1.49
  • Revenue
  • PCRX $716,791,000.00
  • LOB $434,209,000.00
  • Revenue This Year
  • PCRX $7.27
  • LOB $44.86
  • Revenue Next Year
  • PCRX $10.18
  • LOB $16.20
  • P/E Ratio
  • PCRX $50.52
  • LOB $21.57
  • Revenue Growth
  • PCRX 3.14
  • LOB 7.02
  • 52 Week Low
  • PCRX $16.29
  • LOB $22.68
  • 52 Week High
  • PCRX $27.64
  • LOB $49.28
  • Technical
  • Relative Strength Index (RSI)
  • PCRX 56.14
  • LOB 52.28
  • Support Level
  • PCRX $22.29
  • LOB $29.36
  • Resistance Level
  • PCRX $24.95
  • LOB $32.47
  • Average True Range (ATR)
  • PCRX 1.23
  • LOB 1.06
  • MACD
  • PCRX 0.09
  • LOB 0.25
  • Stochastic Oscillator
  • PCRX 78.19
  • LOB 78.86

About PCRX Pacira BioSciences Inc.

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

About LOB Live Oak Bancshares Inc.

Live Oak Bancshares Inc operates as the bank holding company for the Live Oak Banking Company. The company specializes in lending and deposit-related services to small businesses nationwide. The company identifies and extends lending to credit-worthy borrowers both within specific industries, also called verticals, through expertise within those industries, and more broadly to select borrowers outside of those industries. A portion of the loans originated by the Bank are partially guaranteed by the Small Business Administration under the 7(a) Loan Program and the U.S. Department of Agriculture Rural Energy for America Program, Water and Environmental Program, Business and Industry and Community Facilities loan programs.

Share on Social Networks: